About: The management of patients with metastatic prostate cancer during the COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The management of patients with metastatic prostate cancer during the COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The management of patients with metastatic prostate cancer during the COVID-19 pandemic
Creator	Abboud, Rita-Maria Assi, Tarek Ibrahim, Nathalie Kattan, Joseph Kattan, Clarisse Nemr, Elie Rassy, Elie
Source	Medline; PMC
abstract	During the ongoing global pandemic of coronavirus disease 2019 (COVID-19), the benefit of treating patients with cancer must be weighed against the COVID-19 infection risks to patients, staff and society. Prostate cancer is one of the most common cancers among men and raises particular interest during the pandemic as recent reports show that the TMPRSS2 (and other serine proteases), which facilitate the entry, replication and budding of the virion from a cell, can be inhibited using androgen deprivation therapy. Nevertheless, patients with metastatic prostate cancer commonly receive chemotherapy which may compromise their immune system. This paper aims to address the current status of the COVID-19 in patients with cancer overall and suggests an optimal approach to patients with metastatic prostate cancer.
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.2217/fon-2020-0361
bibo:pmid	32412310
has license	cc-by
sha1sum (hex)	91cf28fb2f0660d7ec8d57585cb534aade269610
schema:url	https://doi.org/10.2217/fon-2020-0361
resource representing a document's title	The management of patients with metastatic prostate cancer during the COVID-19 pandemic
has PubMed Central identifier	PMC7426764
has PubMed identifier	32412310
schema:publication	Future oncology
resource representing a document's body	covid:91cf28fb2f0660d7ec8d57585cb534aade269610#body_text
is schema:about of	named entity 'men' named entity 'Nevertheless' named entity 'androgen' named entity 'immune system' named entity 'pandemic' named entity 'commonly' named entity 'Prostate cancer' named entity 'serine proteases' named entity 'Prostate cancer' named entity 'metastatic prostate cancer' named entity 'replication' named entity 'compromise' named entity 'chemotherapy' named entity 'androgen deprivation therapy' named entity 'denosumab' named entity 'Grade 3' named entity 'control arm' named entity 'Lung cancer' named entity 'docetaxel' named entity 'COVID-19' named entity 'tumor' named entity 'enzalutamide' named entity 'hormone' named entity 'hormonal therapy' named entity 'febrile neutropenia' named entity 'chemotherapeutic agents' named entity 'neutropenic' named entity 'cross-resistance' named entity 'docetaxel' named entity 'docetaxel' named entity 'Docetaxel' named entity 'EMA' named entity 'metastatic' named entity 'infection' named entity '95% CI' named entity 'Docetaxel' named entity 'febrile neutropenia' named entity 'prognosis' named entity 'infection' named entity 'abiraterone acetate' named entity 'COVID' named entity 'infection' named entity 'ADT' named entity 'tumor' named entity 'serine proteases' named entity 'antiviral therapy' named entity 'ADT' named entity 'castrate' named entity 'febrile neutropenia' named entity '95% CI' named entity 'apalutamide' named entity 'docetaxel' named entity 'metastatic' named entity 'ACE inhibitors' named entity '95% CI' named entity 'COVID' named entity 'radiation therapy' named entity 'enzalutamide' named entity 'enzalutamide' named entity 'mitoxantrone' named entity 'metastatic prostate cancer' named entity 'COVID-19' named entity 'androgen deprivation therapy' named entity 'higher risk' named entity 'docetaxel' named entity 'apalutamide' named entity '95% CI' named entity 'chemotherapy' named entity 'neutropenia' named entity 'febrile neutropenia' named entity 'neutropenia' named entity 'chemotherapy' named entity 'Radiotherapy' named entity 'prednisolone' named entity 'ADT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software